课题基金 / 基金详情

MiR-204 regulates type 1 IP3R/Ca2+ axis to control vascular smooth muscle cell contractility and blood pressure: Potential role of the gut microbiome

MiR-204 regulates type 1 IP3R/Ca2+ axis to control vascular smooth muscle cell contractility and blood pressure: Potential role of the gut microbiome
MiR-204 调节 1 型 IP3R/Ca2 轴以控制血管平滑肌细胞收缩性和血压:肠道微生物组的潜在作用
批准号:
10291115
负责人:
Modar O. Kassan
金额:
$45.64万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-09-01 至 2025-06-30

项目摘要

项目成果

Modar O. Kassan的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary Hypertension is the most prevalent cardiovascular disorder worldwide. Deregulation of vascular smooth muscle cell (VSMC) contraction is a final common pathway in hypertension. Intracellular calcium (Ca2+) is a trigger and key determinant of VSMC contraction. Vascular smooth muscle cytosolic Ca2+ concentration is tightly regulated by Ca2+ influx and efflux from the extracellular space and from intracellular stores, most notably the sarcoplasmic reticulum. Inositol 1,4,5- trisphosphate (IP3) through its receptors (IP3R) controls Ca2+ release form the sarcoplasmic reticulum into the cytoplasm. Hypertension is a multi-system disease. Disruption of homeostatic mechanisms in distant organs can affect vascular tone. As one example, bacteria that inhabit the gut (gut microbiome) can modulate blood pressure. Normotensive animals become hypertensive when transplanted with gut microbiota from hypertensive animals, and vice versa. Furthermore, hypertension in humans is associated with specific alterations in gut microbial diversity, lending credence to the premise that a change in gut microbial load and diversity (dysbiosis) contributes to the pathogenesis of hypertension. Our preliminary data shows that dysbiosis in mice caused by broad-spectrum antibiotics leads to hypercontractility of blood vessels and associated upregulation of IP3R1. In addition, we have evidence that broad-spectrum antibiotics downregulate expression of miR-204, a microbiome-sensitive microRNA, in vascular smooth muscle cells. Moreover, miR-204 targets IP3R1, and mice with global deletion of miR-204 are susceptible to developing hypertension. We therefore hypothesize that miR-204 is a key regulator of VSMC contractility, and its downregulation due to gut microbial dysbiosis promotes hypertension. This application will examine the role of miR-204 in regulating VSMC Ca2+ and explore the mechanisms by which it does so. It will use mice with deletion of miR-204 and IP3R1 in VSMC, and state-of-the-art methodologies to assess Ca2+ flux in cells and in vessels of live animals. Using these unique tools, and with the assembled expertise, it will determine if miR-204 controls blood pressure, VSMC Ca2+ homeostasis and VSMC contraction via IP3R1. In addition, it will blaze a trail connecting the gut microbiome and regulation of vascular tone, by determining if gut microbial dysbiosis disrupts VSMC Ca2+ homeostasis, and promotes hypertension through downregulation of miR-204. Information gained from this work will be a vertical advancement in the field of hypertension research.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
MiR-204 regulates type 1 IP3R/Ca2+ axis to control vascular smooth muscle cell contractility and blood pressure: Potential role of the gut microbiome
MiR-204 regulates type 1 IP3R/Ca2+ axis to control vascular smooth muscle cell contractility and blood pressure: Potential role of the gut microbiome
国内基金
海外基金
外泌体lncRNA TUG1通过miR-204-5p/FOXC1信号通路靶向调控HUVECs促进肝母细胞瘤血管生成的机制研究
  • 批准号:
    2026JJ81317
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    袁妙贤
  • 依托单位:
母乳外泌体源 miR-204-3p 通过 IL1R1 调控肠黏膜屏障对新生儿坏死性小肠结肠炎的干预及机制研究
  • 批准号:
    2026JJ80525
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    陈振江
  • 依托单位:
miR204-5p通过AKAP1/MTP18调控线粒体融合/分裂参与胸主动脉夹层动脉瘤的机制研究
  • 批准号:
    JCZRYB202500200
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
脂肪干细胞外泌体递送circPpm1d调控miRNA-204-3p/GPR157网络抑制肺泡巨噬细胞焦亡:慢阻肺治疗新机制
  • 批准号:
    2024Y9410
  • 项目类别:
    省市级项目
  • 资助金额:
    15.0万元
  • 批准年份:
    2024
  • 负责人:
    朱志兴
  • 依托单位: